Cargando…
The Endocannabinoid System, Cannabinoids, and Pain
The endocannabinoid system is involved in a host of homeostatic and physiologic functions, including modulation of pain and inflammation. The specific roles of currently identified endocannabinoids that act as ligands at endogenous cannabinoid receptors within the central nervous system (primarily b...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rambam Health Care Campus
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3820295/ https://www.ncbi.nlm.nih.gov/pubmed/24228165 http://dx.doi.org/10.5041/RMMJ.10129 |
_version_ | 1782290115713826816 |
---|---|
author | Fine, Perry G. Rosenfeld, Mark J. |
author_facet | Fine, Perry G. Rosenfeld, Mark J. |
author_sort | Fine, Perry G. |
collection | PubMed |
description | The endocannabinoid system is involved in a host of homeostatic and physiologic functions, including modulation of pain and inflammation. The specific roles of currently identified endocannabinoids that act as ligands at endogenous cannabinoid receptors within the central nervous system (primarily but not exclusively CB(1) receptors) and in the periphery (primarily but not exclusively CB(2) receptors) are only partially elucidated, but they do exert an influence on nociception. Exogenous plant-based cannabinoids (phytocannabinoids) and chemically related compounds, like the terpenes, commonly found in many foods, have been found to exert significant analgesic effects in various chronic pain conditions. Currently, the use of Δ9-tetrahydrocannabinol is limited by its psychoactive effects and predominant delivery route (smoking), as well as regulatory or legal constraints. However, other phytocannabinoids in combination, especially cannabidiol and β-caryophyllene, delivered by the oral route appear to be promising candidates for the treatment of chronic pain due to their high safety and low adverse effects profiles. This review will provide the reader with the foundational basic and clinical science linking the endocannabinoid system and the phytocannabinoids with their potentially therapeutic role in the management of chronic pain. |
format | Online Article Text |
id | pubmed-3820295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Rambam Health Care Campus |
record_format | MEDLINE/PubMed |
spelling | pubmed-38202952013-11-13 The Endocannabinoid System, Cannabinoids, and Pain Fine, Perry G. Rosenfeld, Mark J. Rambam Maimonides Med J Special Issue on Pain The endocannabinoid system is involved in a host of homeostatic and physiologic functions, including modulation of pain and inflammation. The specific roles of currently identified endocannabinoids that act as ligands at endogenous cannabinoid receptors within the central nervous system (primarily but not exclusively CB(1) receptors) and in the periphery (primarily but not exclusively CB(2) receptors) are only partially elucidated, but they do exert an influence on nociception. Exogenous plant-based cannabinoids (phytocannabinoids) and chemically related compounds, like the terpenes, commonly found in many foods, have been found to exert significant analgesic effects in various chronic pain conditions. Currently, the use of Δ9-tetrahydrocannabinol is limited by its psychoactive effects and predominant delivery route (smoking), as well as regulatory or legal constraints. However, other phytocannabinoids in combination, especially cannabidiol and β-caryophyllene, delivered by the oral route appear to be promising candidates for the treatment of chronic pain due to their high safety and low adverse effects profiles. This review will provide the reader with the foundational basic and clinical science linking the endocannabinoid system and the phytocannabinoids with their potentially therapeutic role in the management of chronic pain. Rambam Health Care Campus 2013-10-29 /pmc/articles/PMC3820295/ /pubmed/24228165 http://dx.doi.org/10.5041/RMMJ.10129 Text en © 2013 Fine and Rosenfeld. This is an open-access article. All its content, except where otherwise noted, is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Special Issue on Pain Fine, Perry G. Rosenfeld, Mark J. The Endocannabinoid System, Cannabinoids, and Pain |
title | The Endocannabinoid System, Cannabinoids, and Pain |
title_full | The Endocannabinoid System, Cannabinoids, and Pain |
title_fullStr | The Endocannabinoid System, Cannabinoids, and Pain |
title_full_unstemmed | The Endocannabinoid System, Cannabinoids, and Pain |
title_short | The Endocannabinoid System, Cannabinoids, and Pain |
title_sort | endocannabinoid system, cannabinoids, and pain |
topic | Special Issue on Pain |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3820295/ https://www.ncbi.nlm.nih.gov/pubmed/24228165 http://dx.doi.org/10.5041/RMMJ.10129 |
work_keys_str_mv | AT fineperryg theendocannabinoidsystemcannabinoidsandpain AT rosenfeldmarkj theendocannabinoidsystemcannabinoidsandpain AT fineperryg endocannabinoidsystemcannabinoidsandpain AT rosenfeldmarkj endocannabinoidsystemcannabinoidsandpain |